UK’s National Institute for Health and Care Excellence recommended against the NHS reimbursing Sanofi’s Cerdelga and Bristol-Myers Squibb’s Opdivo.

In draft appraisals, the UK’s price watchdog concluded that the clinical evidence to support Cerdelga’s long-term benefits and value remain uncertain.

NICE acknowledged that the Sanofi’s drug might be an effective treatment for type 1 Gaucher disease, but noted the need for more robust data to demonstrate the drug’s long-term benefits.

NICE said the data supporting Opdivo’s clinical effectiveness is “immature” and reimbursement would not be a cost-effective use of NHS resources.